A new assay based on solid-phase extraction procedure with LC-MS to measure plasmatic concentrations of tenofovir and emtricitabine in HIV infected patients.

A new solid-phase extraction (SPE) method has been developed and validated on a liquid chromatography (LC) coupled with a mass spectrometer for the determination of plasma concentrations of tenofovir (TNF) and emtricitabine (FTC) in HIV infected patients. Chromatographic separation was achieved with a gradient (acetonitrile and water with formic acid 0.05%) on an Atlantis 4.6 mm x 150 mm, reversed phase analytical column. Detection of TNF, FTC, and internal standard (IS) was achieved by electrospray ionization mass spectrometry (ESI-MS) in the positive ion mode. Calibration ranged from 15.6 to 4000 ng/mL for TNF and 11.7 to 3000 ng/mL for FTC. Plasma was analyzed, and the limit of quantitation was 15.6 ng/mL for TNF and 11.7 ng/mL for FTC; limit of detection was 2 ng/mL for TNF and 1.5 ng/mL for FTC. Mean recovery of TNF, FTC, and IS were 46.5% [relative standard deviation (RSD): 8.8%] and 88.8% (RSD: 1.0%), and 81.7% (RSD: 3.1%), respectively. The method did not show any significant interference with antiretrovirals or other concomitant drugs administered to patients, and no significant "matrix effects" were observed. The method was applied for the determination of antiretroviral plasma concentration of HIV-positive patients treated with FTC and/or TNF, in combination with various other antiretrovirals.

[1]  Jérôme Guitton,et al.  Relevance of a combined UV and single mass spectrometry detection for the determination of tenofovir in human plasma by HPLC in therapeutic drug monitoring. , 2007, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[2]  R. Ebrahimi,et al.  Pharmacokinetics and Safety of Tenofovir Disoproxil Fumarate on Coadministration With Lopinavir/Ritonavir , 2006, Journal of acquired immune deficiency syndromes.

[3]  R. Schinazi,et al.  Pharmacology of current and promising nucleosides for the treatment of human immunodeficiency viruses. , 2006, Antiviral research.

[4]  S. Khoo,et al.  An Update on Therapeutic Drug Monitoring for Antiretroviral Drugs , 2006, Therapeutic drug monitoring.

[5]  R. Rathbun,et al.  Current HIV treatment guidelines--an overview. , 2006, Current pharmaceutical design.

[6]  C. Fletcher,et al.  Sensitive assay for determining plasma tenofovir concentrations by LC/MS/MS. , 2006, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[7]  P. Anzenbacher,et al.  Inhibition of human liver microsomal cytochrome P450 activities by adefovir and tenofovir , 2006, Xenobiotica; the fate of foreign compounds in biological systems.

[8]  A. Kashuba,et al.  Simultaneous quantification of emtricitabine and tenofovir in human plasma using high-performance liquid chromatography after solid phase extraction. , 2005, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[9]  P. Taylor.  Matrix effects: the Achilles heel of quantitative high-performance liquid chromatography-electrospray-tandem mass spectrometry. , 2005, Clinical biochemistry.

[10]  Joel E Gallant,et al.  Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. , 2004, JAMA.

[11]  V. Soriano,et al.  Tenofovir-related nephrotoxicity in HIV-infected patients. , 2004, AIDS.

[12]  A. Ray,et al.  Role of Purine Nucleoside Phosphorylase in Interactions between 2′,3′-Dideoxyinosine and Allopurinol, Ganciclovir, or Tenofovir , 2004, Antimicrobial Agents and Chemotherapy.

[13]  W. Rozenbaum,et al.  Pharmacokinetics of emtricitabine, didanosine and efavirenz administered once‐daily for the treatment of HIV‐infected adults (pharmacokinetic substudy of the ANRS 091 trial) * , 2004, HIV medicine.

[14]  H. Izzedine,et al.  Pharmacokinetics of tenofovir in haemodialysis. , 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[15]  P. Lechat,et al.  Sensitive determination of tenofovir in human plasma samples using reversed-phase liquid chromatography. , 2003, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[16]  K. Dalhoff,et al.  Acute renal failure associated with tenofovir treatment in a patient with acquired immunodeficiency syndrome. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  J. Schellens,et al.  Liquid chromatographic assay for the antiviral nucleotide analogue tenofovir in plasma using derivatization with chloroacetaldehyde. , 2003, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[18]  E. Acosta,et al.  Therapeutic drug monitoring in the treatment of HIV-infection. , 2003, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[19]  D. Droz,et al.  Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients: three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  M. Kazatchkine,et al.  Renal lesions in HIV-1-positive patient treated with tenofovir. , 2003, AIDS.

[21]  V. Jullien,et al.  Determination of tenofovir in human plasma by high-performance liquid chromatography with spectrofluorimetric detection. , 2003, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[22]  R. Haubrich,et al.  Therapeutic drug monitoring in HIV infection: current status and future directions , 2002, AIDS.

[23]  J. Kahn,et al.  Phase I/II Trial of the Pharmacokinetics, Safety, and Antiretroviral Activity of Tenofovir Disoproxil Fumarate in Human Immunodeficiency Virus-Infected Adults , 2001, Antimicrobial Agents and Chemotherapy.

[24]  P. Kissinger,et al.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. , 1998, The New England journal of medicine.

[25]  G. Satten,et al.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. , 1998, The New England journal of medicine.

[26]  William A. Lee,et al.  Pharmacokinetics and Bioavailability of the Anti-Human Immunodeficiency Virus Nucleotide Analog 9-[(R)2-(Phosphonomethoxy)Propyl]Adenine (PMPA) in Dogs , 1998, Antimicrobial Agents and Chemotherapy.

[27]  B. Yip,et al.  Decline in deaths from AIDS due to new antiretrovirals , 1997, The Lancet.

[28]  A. Park,et al.  CENTER FOR DRUG EVALUATION AND RESEARCH , 2009 .

[29]  J. Schapiro,et al.  Therapeutic Drug Monitoring , 2012, Drugs.